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The occurrence and spread of multidrug-resistant bacteria is a prominent health
concern. To curb this urgent threat, new innovative strategies pursuing novel
antimicrobial agents are of the utmost importance. Here, we unleashed the antimicrobial
activity of human neutrophil peptide-4 (HNP-4) by tryptic digestion. We identified a
single 11 amino acid long fragment (HNP-41−11) with remarkable antimicrobial potential,
exceeding that of the full length peptide on both mass and molar levels. Importantly,
HNP-41−11 was equally bactericidal against multidrug-resistant and non-resistant
strains; a potency that was further enhanced by N- and C-terminus modifications
(acetylation and amidation, respectively). These observations, combined with negligible
cytotoxicity not exceeding that of the full length peptide, presents proteolytic digestion of
innate host-defense-peptides as a novel strategy to overcome the current health crisis
related to antibiotic-resistant bacteria.
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INTRODUCTION
The spread and occurrence of new multidrug-resistant bacteria represents a prominent and
emerging health care threat on a global scale. At large, the pharmaceutical industry and
governments alike have failed to develop new antibiotics which has urged World Health
Organization (WHO) to call out for new cost-effective strategies to fight these devastating
pathogens (Tacconelli et al., 2018). A major challenge is the divergent motivation from society
vs. companies, where novel strategies are welcomed yet shelved by regulatory authorities. The
rationale behind such decisions, mitigating the risk of multidrug resistance while ensuring these
novel therapies in case of an outbreak, is justified, yet jeopardizes the costly development of novel
antibiotics. Thus, new cost-effective strategies more resilient to multidrug resistance are urgently
needed (Sukkar, 2013; Falagas et al., 2016). Host-defense-peptides (HDP) – previously known as
antimicrobial peptides (AMPs) – possess a broad range of antimicrobial properties, which could
be useful to develop new antimicrobials in the fight against resistant pathogens (Zasloff, 2002).
Defensins are the most prominent class of HDPs in humans. These small cationic molecules share
as a common motive six conserved cysteines, which from three disulfide bonds classifies them
into α- and β-defensins (White et al., 1995; Ganz, 2003; Selsted and Ouellette, 2005). Four of the
six human α-defensins are expressed by immune cells, namely human neutrophil peptides 1–4
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(HNPs), whereas the remaining two, human α-defensin 5 and
6 (HD-5 and HD-6) are expressed by Paneth cells in the small
intestine (Lehrer and Lu, 2012). All HNPs are processed from
propeptide to mature form during their trafficking activated
by proteolytic digestion in polymorphonuclear neutrophils
azurophilic granules (Valore and Ganz, 1992). These granules
fuse with the lysosome after phagocytosis of pathogens allowing
for context specific bactericidal activity (Ganz et al., 1985; Selsted
et al., 1985). Based on the biological control of these processes it
is hypothesized that synthetic production of said peptides could
be used as an antibiotic tool against extracellular pathogens.
Yet, large-scale expression of accurately folded defensins is a
major cost-challenge. Inspired by our recent observation that
duodenal fluid degrades full length HD-5 to multiple biological
active fragments with different antimicrobial properties including
potency, efficacy and bacterial spectrum (Ehmann et al., 2019),
we hypothesized that enzymatic digestion of mature HDPs could
unleash their antimicrobial capacity and concomitantly solve the
production-cost challenge of full length peptides. To this end,
the least expressed HNP, HNP-4 (Harwig et al., 1992; Hu et al.,
2019), is more bactericidal against Gram-negative bacteria than
any of HNP-1-3 (Ericksen et al., 2005). While HNP-1-3 only
differs internally in the first amino acid sequence, HNP-4 is more
divergent combined with an increased negative charge ultimately
enhancing antimicrobial activity (Lehrer and Lu, 2012). We
used HNP-4 as precursor to identify new therapeutic agents. To
this end, tryptic digestion of the linearized full length peptide
liberated its antimicrobial potential. We identified a single
fragment with a remarkable bactericidal potency, exceeding the
MIC of the full length peptide on molar level. Surprisingly, we
observed the antimicrobial efficacy of said peptide to be equally
efficient against multidrug-resistant and non-resistant strains,
hence presenting HDP fragmentation (Latendorf et al., 2019)
as an innovative and cost-effective strategy to aid curbing the
emerging threat of antibiotic resistance.
MATERIALS AND METHODS
Bacterial Strains
B. adolescentis Ni3,29c and B. breve were provided by
Ardeypharm GmbH (Herdecke, Germany). L. rhamnosus
GG was obtained from InfectoPharm Arzneimittel and
Consilium GmbH (Heppenheim, Germany). A. baumannii
DSM30007, B. vulgatus DSM1447, E. coli MC1000 DSM6214,
E. coli DSM8695 (EPEC), E. coli DSM10729 (UPEC), E. faecalis
DSM20478, E. faecium DSM20477, K. pneumoniae DSM30104,
and S. epidermidis DSM20044 were obtained from Deutsche
Sammlung von Mikroorganismen und Zellkultur GmbH
(Braunschweig, Germany). A. baumannii 4-MRGN, B. longum,
E. coli ATCC25922, E. faecium, E. faecalis ATCC29212,
K. pneumoniae 3-MRGN, L. fermentum, L. salivarius,
P. aeruginosa ATCC27853, P. aeruginosa 4-MRGN, S. enterica
serovar Enteritidis, S. aureus ATCC25923 and S. salivarius
were obtained as clinical isolates from the Robert-Bosch-
Hospital Stuttgart, Germany. B. subtilis (trpC2), E. coli JM83,
P. aeruginosa PAO1, P. aeruginosa XPAT1, P. aeruginosa XPAT2,
S. aureus USA300 and Y. enterocolitica were provided by the
Interfaculty Institute for Microbiology and Infection Medicine,
Tübingen, Germany.
Peptides
HNP-4 (Purity ≥ 99%) was obtained from PeptaNova GmbH
(Sandhausen, Germany). All peptide fragments, HNP-41−11
and HNP-41−11mod were chemically synthesized by EMC
Microcollections GmbH (Tübingen, Germany) and purified by
precipitation. EMC Microcollections guarantees a purity >>
90% by HPLC analysis (Supplementary Figure S3). All peptides
were dissolved in 0.01% acetic acid.
Screening for Fragments of HNP-4 Using
LC/MS
As previously described (Ehmann et al., 2019), 2.5 µg of HNP-
4 were incubated in 50 mM NH4HCO3 buffer (pH 8.0; Fluka)
with 2 mM tris (2-carboxyethyl) phosphine for 15 min at
37◦C. Afterward, 0.05 µg trypsin [1:50 (w/w)] was added and
incubated for additional 30 min at 37◦C. Lastly, formic acid and
acetonitrile in a final concentration of 0.5 and 10% were added,
respectively, and the samples analyzed by mass spectrometry.
Mass spectrometry was performed as a LC/MS system using an
Agilent 1200 series HPLC with an Agilent Advanced Bio Peptide
Map (2.1 × 150 mm, 2.7 µm) column with a flow of 0.4 ml/min
at 55◦C column temperature and a 6540 UHD Q-TOF LC/MS
system (Agilent) for mass analysis. The samples were separated
by a gradient of acetonitrile in 0.1% formic acid. The gradient
started at 2% acetonitrile for 4 min and then increases during
35 min to 45%. Mass spectrometric analyses were performed in
single MS mode from 100 to 3400 m/z with positive ion polarity
and were analyzed by Agilent MassHunter Quantitative Analysis
B 06.00 software.
Screening for Potential Dimers of
HNP-41−11 and HNP-41−11mod Using
HPLC-MS
To analyze possible inter-/intramolecular dimer formation
HPLC-MS were performed by EMC Microcollections GmbH
Tübingen. HPLC-MS was performed using a Chromolith
Fast Gradient RP18e, 50 × 2 mm column (Merck) with
detection at a wavelength of 214 nm, followed by an ESI-MS
analysis. The samples were separated by a gradient of MeCN
(acetonitrile) containing 0.1% FA (monofluoroacetic acid) from
0 to 100% in 30 min.
Radial Diffusion Assay
Antimicrobial activity of all peptides was assessed with a
modified version of the radial diffusion assay as described
earlier (Schroeder et al., 2011b). Briefly, bacteria were cultivated
(anaerobic bacteria in anaerobic jars with AnaeroGen, Oxoid,
United Kingdom) for up to 18 h in liquid TSB medium. Log-
phase bacteria were washed with 10 mM sodium phosphate
buffer; pH 7.4 and diluted to 4 × 106 CFU/ml in 10 ml agar
(10 mM sodium phosphate buffer, pH 7.4 with 0.3 mg/ml
TSB powder and 1% (w/v) low EEO-agarose (AppliChem).
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Bacteria were incubated under aerobic or anaerobic conditions,
respectively, with 2 µg HNP-4 or 4 µg of each fragment for
3 h at 37◦C. Afterward, plates were covered with 10 ml of an
overlay-gel containing 6% (w/v) TSB powder, 1% (w/v) agar and
10 mM sodium phosphate buffer and incubated for 24 h. The
diameter of the inhibition zones corresponds to the antimicrobial
activity, when subtracting the diameter of 2.5 mm corresponding
to the diameter of the punched well. Experiments were repeated
at least three times.
Turbidity Broth Assay
Log-phase bacteria were washed twice with 10 mM sodium
phosphate buffer containing 1% (w/v) TSB. Approximately
4 × 105 CFU/ml bacteria were incubated with serial peptide
concentrations (1.56–100 µM) in a final volume of 100 µl in
10 mM sodium phosphate buffer containing 1% (w/v) TSB for
2 h at 37◦C. Afterward, 100 µl of 6% TSB (w/v) were added and
absorbance was measured at 600 nm (Tecan, Switzerland) and
monitored for 12 h. Experiments were carried out at least three
independent times.
Time-Kill Assay
Log-phase bacteria (5 × 105 CFU/ml) were incubated with
6.25 µM of HPN-4fl, HNP-41−11, HNP-41−11mod or 0.01%
acetic acid as a control in 10 mM sodium phosphate buffer
containing 1% (w/v) TSB. After incubation at 37◦C and 150 rpm
for 0 to 120 min, a sample was taken from the suspension
and added to a 0.05% (v/v) sodium polyanethole sulfonate
(Sigma-Aldrich) solution, which neutralizes remaining peptide
activity, and plated on LB agar to determine the number of
viable bacteria. Experiments were carried out at least three
independent times.
Reduction Assay
The amino acid sequences of HNP-41−11 and HNP-41−11mod
contain cysteines which might form disulfide bonds with
another fragment. As reducing agent Dithiothreitol (DTT) was
used. Both peptides, HNP-41−11 and HNP-41−11mod were pre-
incubated with either 0.1 mM or 1 mM DTT for 1 h at
room temperature followed by a turbidity broth assay with
˜4 × 105 CFU/ml bacteria as described above. The MIC of
HNP-41−11 and HNP-41−11mod was determined against different
bacteria strains. Experiments were carried out at least three
independent times.
Protease Inhibitor Assay
Log-phase bacteria were cultivated for up to 18 h in TSB
containing different concentrations (0.01 or 0.1) of Bacterial
ProteaseArrestTM (G-Biosciences) and 0.5 M EDTA. Bacteria
were washed with twice with 10 mM sodium phosphate
buffer containing 1% (w/v) TSB and the optical density at
600 nm was adjusted to 0.1. Approximately 5 × 105 CFU/ml
bacteria were incubated with serial peptide concentrations (1.56–
12.5 µM) in a final volume of 100 µl in 10 mM sodium
phosphate buffer containing 1% (w/v) TSB and (0.01 or 0.1) of
Bacterial ProteaseArrestTM and 0.5 M EDTA for 2 h at 37◦C.
After incubation, 100 µl of 6% TSB (w/v) were added and
absorbance was measured at 600 nm (Tecan, Switzerland) and
monitored for 12 h. Experiments were carried out at least three
independent times.
Cell Toxicity Assay
Experiments were conducted with the human colonic epithelial
adenocarcinoma cell line CaCo2 subclone TC7 which was
obtained from the Robert-Bosch-Hospital Stuttgart, Germany.
HT29 MTX cells subclone E12 (Merck, Germany) were
used as an additional colorectal carcinoma cell line. Cells
were used at an internal early passage of about 25–40. For
experiments, 1500 cells/well were seeded in a 96-well plate in
90 µl media.
Cells were treated with serial peptide concentrations (1.56–
100 µM) in a final volume of 100 µl and incubated for 96 h.
Afterward, the CellTiter-Glo R© 2.0 Cell Viability Assay (Promega,
United States) was performed based on the company’s protocol.
Experiments were carried out at least three independent times.
Hemolytic Activity of HNP4 Fragments
Hemolytic activity assay was performed as described earlier
(Oddo and Hansen, 2017). Briefly, 1 ml O neg whole blood was
washed twice with PBS, centrifuged and 1% (v/v) erythrocytes
suspension prepared. Erythrocytes were incubated with serial
peptide concentrations (1.56–100 µM) for 1 h at 37◦C. Then,
samples were centrifuged, supernatant collected and optical
density measured at 414 nm. Toxicity against erythrocytes
was relative determined to the hemolytic activity of 0.1%
Triton X-100. Experiments were carried out in duplicates and
performed twice.
Ethics Statement
The study protocol was previously approved by the Ethical
Committee of the University Hospital Tübingen, Germany.
Patients and controls who were included in this study all gave
their written and informed consent after the study purpose,
samples procedure, and potential adjunctive risks were explained.
All experiments were conducted in accordance with the relevant
guidelines and regulations.
RESULTS
Identification of a Novel HNP-4 Fragment
After Tryptic Digestions
To generate possible fragments out of HNP-4 we used
trypsin as a serine protease. It is known from previous work
that folded defensins seemed to be stable against proteolytic
digestion (Schroeder et al., 2011a). We incubated HNP-
4 with 2 mM TCEP (tris(2-carboxyethyl)phosphine; Sigma-
Aldrich) to open the disulfide bonds leading to a more
linear structure susceptible to proteolytic digest. We analyzed
the trypsin-incubated reduced HNP-4 via LC/MS methods
and were able to detect several fragments according to the
observed ions and their mass to charge ratio (Figure 1A).
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Identified fragments were mostly located in the N-terminal
region based on the cleaving sites of trypsin (Figure 1B).
As it is commonly accepted that the net charge of AMPs
could play an important role to their antimicrobial activity,
we focused on HNP-41−11 with a positive net charge of +3
Figure 1B, marked in red.
Antimicrobial Efficacy of HNP-41−11 and
HNP-41−11mod
The natural in vivo stability of short linear peptides is
generally weak; we therefore used an additional modified
form of HNP-41−11 (HNP-41−11mod). Here we exchanged
the L-amino acids with D-amino acids and modified the
N-terminus (acetylation) and C-terminus (amidation). Both
modifications should result in a gain of stability (Brinckerhoff
et al., 1999; Hong et al., 1999), hence potentially leading to
a stronger antimicrobial activity. To analyze the antimicrobial
activity of HNP-4fl, HNP-41−11, and HNP-41−11mod we used
RDAs against a subset of different commensal and pathogenic
bacteria (Supplementary Figures S1, S2). All of our tested
peptides showed an antimicrobial activity against tested bacteria
(Figure 2). While the RDA is the suitable assay to determine a
general antimicrobial activity of different peptides, a comparison
between different peptides is not possible according to their
different abilities (like diffusion) in an agarose gel. We therefore
next used a turbidity broth assay to determine the minimal
inhibitory concentration (MIC) of HNP-4fl, HNP-41−11, and
HNP-41−11mod against pathogenic (some multidrug-resistant)
Gram negative and positive bacteria (Figure 3A). While all
peptides displayed antimicrobial activity against tested bacteria
(sole exception: HNP-4fl against K. pneumoniae DSM30104),
HNP-41−11 was surprisingly equimolar to HNP-4fl, indicating
that the antimicrobial potency of the natural complex-to-produce
HNP-4fl is chiefly driven by the first 11 amino acids (HNP-41−11),
at least in its linear form. To this end, Hu and colleagues recently
observed some dependency of specific residues post position 11 in
the fully folded native peptide (Hu et al., 2019). Pointing further
toward enhanced bactericidal efficacy of this linear fragment,
HNP-41−11mod, which is expected to exhibit increased stability
over the non-modified version, was superior to both HNP-4fl and
HNP-41−11 with a MIC several fold lower than the one observed
for the natural occurring full length peptide. Additionally, we
performed a time-kill assay to investigate the efficacy of HNP-
41−11 and HNP-41−11mod compared to the HNP-4fl. Although
we observed a higher potency of HNP-41−11, the efficacy was
similar to HNP-4. In contrast, HNP-41−11mod was superior in
both aspects (Figure 3B).
In vitro Stability of HNP-41−11 and
HNP-41−11mod
We modified the turbidity broth assay to determine the stability
and potential resistance against proteolysis and/or natural
degradation. To this end, we determined the antimicrobial
activity of HNP-41−11 and HNP-41−11mod against E. coli
ATCC25922 in presence a protease inhibitor cocktail
(Figure 4A). Increasing amounts of protease inhibitors did
not improve the bactericidal potential of any of the tested
fragments, indicating bacterial proteases do not further degrade
mentioned fragments, hence corroborating their stability.
Instead, the data points toward a potential fragment:protease
interaction, as high concentrations of protease inhibitors reduced
the bactericidal efficacy of both fragments.
Enhanced prevalence of cysteine residues on most HDPs led
to the current models of multimer formation, combined with
a high net charge, as a mechanism to interact with the surface
of microorganisms (Brogden, 2005; Mukherjee and Hooper,
2015). To address if multimers were essential for bactericidal
efficacy, we determined the MIC of HNP-41−11 and HNP-
41−11mod against E. coli ATCC25922 in the presence of increasing
levels of the reducing agent, DTT (Figure 4B). Elevated DTT
concentrations did not affect antimicrobial activity of neither
HNP-41−11 nor HNP-41−11mod, suggesting that monomeric
peptides were sufficient to kill E. coli ATCC25922. To further
substantiate these observations, we next performed a HPLC-
MS analysis to determine possible inter-/intramolecular dimer
formation (Figures 4C,D). In line with the results from our
reduction assay, we did not detect any formation of oligomeric
or polymeric peptide fragments.
Cytotoxic and Hemolytic Effects of
HNP-41−11 and HNP-41−11mod
To determine the potential of HNP-41−11 and HNP-41−11mod for
in vivo applications as therapeutic agents, we used two different
cell lines to investigate their cytotoxic abilities.
While we only observed minor cytotoxic effects on
CaCo2/TC7 cells at higher peptide concentration (Figure 5A),
HT29 MTX E29 cells were more susceptible to both peptide-
derivates (Figure 5B). Importantly, at lower concentrations
(e.g., 12.5 µM, where HNP-41−11mod has a strong antibacterial
effect), the fragments exhibited only modest cytotoxicity.
We additionally examined the hemolytic activity of said
peptides (Figure 5C).
While HNP-41−11mod has a 20% hemolytic effect at 150
µM (by far exceeding the highest concentration needed for
bactericidal efficacy) there was negligible toxicity at ≤18.75
µM, i.e., the highest biological relevant concentration.
Thus, compared to the honey bee toxin, Melittin, which
showed an 80% hemolytic effect at 1.25 µM both HNP-
41−11 and HNP-41−11mod appeared with low hemolytic
activity. In conclusion, the cytotoxic concentrations
identified were magnitudes higher than the corresponding
bactericidal concentration.
DISCUSSION
Loss of antibiotic efficacy causes increased number of
hospitalizations, treatment failures and spread of drug-resistant
pathogens (Martens and Demain, 2017). WHO called out
to develop new strategies against Gram-negative bacteria in
general, and in particularly those from the WHO priority list
(Tacconelli et al., 2018). To meet this request, alternatives to
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FIGURE 1 | Proteolytic digestion of reduced HNP-4 by trypsin produced different fragments. (A) Displays an overview of the chromatogram from an incubation of
reduced HNP-4 with trypsin after reduction with 2 mM TCEP. All detectable fragments were marked in red or gray (a–j) and listed due to their retention time. Panel
(B) show the mass-to-charge (m/z) graphs of all detected fragments. In all mass-to-charge graphs we pointed out the neutral mass based on the detected ions. All
peptides marked in red were chose for synthesis and further investigations.
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FIGURE 2 | HNP4-derivates display a high antimicrobial activity against commensal and pathogenic bacteria. We analyzed the antimicrobial potential of the identified
fragment and its modified version against commensal and pathogenic bacteria. In this heat map, we listed all bacteria and the activity of the fragments in RDA against
them. We used 2 µg of the full-length peptide and 4 µg of each fragment. An inhibition zone greater than 8 mm was determined as highly active, between 2.5 and
8 mm as low active, while a diameter of 2.5 mm (diameter of the punched well) was marked as no activity. The heat map is based on three independent experiments.
FIGURE 3 | Comparison of the potency (MIC) and efficacy (killing rate) of HNP-4fl, HNP-41-11 and HNP-41-11mod. (A) The minimal inhibitory concentration (MIC) in
µM and µg/ml as a concentration without any bacterial growth. Peptides were incubated with tested bacteria and changes in optical density (OD600) were measured
after 12 h at 37◦C. If we were able to observe an antimicrobial effect but did not detect a total inhibition of bacterial growth we marked it with “>>>.”Each
experiment was carried out three independent times. (B) Killing of E. coli ATCC25922 after 0–120 min exposure to 6.25 µM (1× MIC) HNP-4fl, HNP-41-11 and
HNP-41-11mod. Results are expressed as the number of viable bacteria (in log10 CFU) per milliliter. Values are means of three independent experiments.
conventional antibiotics are urgently needed (Ghosh et al.,
2019; Theuretzbacher et al., 2019, 2020). Thus, new strategies,
including those of antimicrobial peptide-derivates must, be
developed in the battle against multi-drug resistant bacteria
(Fosgerau and Hoffmann, 2015; Breij et al., 2018). To this end
proteolysis of HD-5 generated various antimicrobial active
peptides with selectivity to certain bacteria (Ehmann et al.,
2019). These fragments possess abilities to shift microbiota
composition without decreasing diversity. Moreover, mice
treated with HD-51−9, the most potent fragment identified,
harbored an increased amount of Akkermansia sp. (Ehmann
et al., 2019). The same could be shown for the human β-defensin
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FIGURE 4 | Reduction as well as proteolysis of HNP-41-11 and HNP-41-11mod have no influence on the antimicrobial activity. (A) Changes in the antimicrobial activity
against E. coli ATCC25923 were analyzed in the presence of a protease inhibitor cocktail. (B) The minimal inhibitory concentration of HNP-41-11 and HNP-41-11mod
was determined against E. coli ATCC25922 under reducing conditions due to the optical density after 12 h. Results from three independent experiments with ±SEM
are represented. (C) ESI-MS analysis of HNP-41-11 to detect potential dimer’s after peptide dilution. (D) Analysis of HNP-41-11mod using ESI-MS to detect potential
dimer’s after peptide dilution.
1, where digestion also led to a diverse set of biological active
antimicrobial fragments (Wendler et al., 2019). This study
complements our earlier reports with the discovery that
proteolytic digestion of HNP-4 led to a highly active easy-to-
produce 11 amino acids short fragment (HNP-41−11) with
a broad antimicrobial spectrum against Gram negative and
Gram positive bacteria. We hypothesize that this interesting
phenomenon represents a general feature of HDPs rather than
being specific to HNP-4, in part based on the observation
that also the N-terminal part of HNP-1 is antimicrobial
active (Varkey and Nagaraj, 2005). It is thus possible that
this method of tryptic digestion of HNP-4 may be used as a
general technique to unleash the antimicrobial potential of
endogenous expressed HDPs to aid curbing the antibiotic
resistance crises.
Interestingly, HNP-41−11 possesses equal or better
antimicrobial activity against bacteria than the full-length
peptide on molar level. A modified version of this fragment
further improved both potency and efficacy. Remarkably,
HNP-41−11mod was highly effective in vitro against various
multidrug-resistant bacteria including A. baumannii 4-MRGN,
K. pneumoniae 3-MRGN and P. aeruginosa 4-MRGN; all top
“members” of the WHO priority and Centers for Disease
Control and Prevention lists (Tacconelli et al., 2018; CDCP,
2019). Lending credence to the hypothesis of modified HDPs
representing an underexplored plethora of drug candidates
against multi-drug-resistant bacteria, a recent study elegantly
corroborated that this exact class of bacteria are more susceptible
to HDPs (Lázár et al., 2018), hence stressing their potential as new
therapeutic agents. While we were able to show that HNP-41−11
and HNP-41−11mod displayed a broad spectrum antimicrobial
activity pattern, we did not focus on their antimicrobial
mechanisms, but the capacity to induce rapid killing of Gram-
negative bacteria indicates membrane interactions as part of the
mode(s) of action. From a general point of view cysteines and
charged amino acids are often relevant for antimicrobial activity
(Jiang et al., 2008). Importance of those amino acids led to the
current models of HDP mechanism forming multimers as well
as the need of charged amino acids to interact with the surface of
microorganisms (Brogden, 2005; Mukherjee and Hooper, 2015).
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FIGURE 5 | HNP-41-11 and HNP-41-11mod show only minor cytotoxic and hemolytic activity at high concentrations. We investigated the cytotoxic activity of
HNP-41-11 and HNP-41-11mod against (A) CaCo2/TC7 or (B) HT29 MTX E 29 cells. We seeded 1500 cells per well and treated them after 24 h with different peptide
concentrations. Living cells were determined after 96 h treatment using a CellTiter Glo2.0 assay. (C) Hemolytic activity on human erythrocytes of the peptides
compared to 0.1% Triton-X treatment. (A,B) Results from three independent experiments with ±SEM are shown, and (C) Results from two independent experiments
with ±SEM are represented.
Due to these observations, we initially assumed that also the
antimicrobial activity of the here presented fragments depended
on dimerization. Yet, our reducing assays followed by HPLC-MC
analysis illustrated that monomeric formation was sufficient for
the observed bactericidal activity, pointing toward a different
mode of action of these hallmark peptide fragments, disputing
the current dogma in the field.
Although covalent dimers are absent, non-covalent oligomeric
forms of both peptides cannot be entirely excluded. Additional
analyses are necessary to determine the importance of
supramolecular peptide forms for antimicrobial activity, as
non-covalent oligomerization can be relevant for antimicrobial
activity of several and in particular amyloid-forming peptides
(Latendorf et al., 2019).
A challenge with HDPs in therapeutic contexts is their
susceptibility to proteolysis by bacterial proteolytic enzymes
(Reijmar et al., 2007), in particular in reduced environments
(Schroeder et al., 2011a), as exemplified by the outer membrane
protease of Salmonella enterica which degrades and thereby
inactivates HDPs, thus supporting an essential role of bacterial
proteases in bacterial resistance to HDPs (Guina et al., 2000).
The conceptual advancement of utilizing protease-degraded
biologically active fragments, as showcased here by trypsin
digest is therefore intriguing. Such fragments should, by
nature, be resistant to further degradation and may prove
valuable to aid fight multi-drug resistant pathogens. In
keeping with this notion, our analysis revealed that HNP-
41−11 and HNP-41−11mod activity was not further boosted
by protease inhibitors, suggesting that proteases per se do
not hamper their function. Instead, high levels of protease
inhibitors appeared to limit the bactericidal efficacy of
both HNP-41−11 and HNP-41−11mod suggesting that these
fragments conversely interact with proteases, rather than
being annulled by them, to induce bacterial killing. Future
studies are warranted to elucidate the extent of such potential
fragment:protease interaction.
For potential therapeutic application, we assessed toxicity
of HNP-41−11 and HNP-41−11mod. Both peptides showed cell-
type dependent cytotoxicity and hemolytic activity at higher
concentrations. To this end, HNP-41−11mod exerted a greater
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impact on CaCo-2 cells, whereas HNP-41−11 possessed higher
cytotoxicity against HT29-MTX E12 cells, but for both tested cell
types the cytotoxic concentration range were magnitudes higher
than the concentrations needed for antimicrobial activity.
In summary, although future in vivo experiments are
warranted to determine the full potential of HNP-41−11 and
HNP-41−11mod, our results demonstrate promising efficacy
of HNP-41−11 and HNP-41−11mod against multidrug-resistant
bacteria. From this point of view, proteolytic digestion of HDPs
could be used to generate new biologically active fragments to
overcome the antibiotic-resistance crisis.
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